Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Abstract
Background Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity. Methods Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients. A single arm meta-analysis of proportions estimated primary outcomes, ≥5%, ≥10%, and ≥15% weight loss, and adverse events (AEs); while meta-analysis of means estimated secondary outcomes. Comparative meta-analysis was conducted between tirzepatide and control arms where mean differences and odds ratios were estimated for continuous and dichotomous outcomes respectively. Results RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively. Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (MD: -12.47 kg, 95% CI: -13.94 kg to -11.00 kg) and semaglutide (n = 1409, MD: -1.90 kg, 95% CI: -2.97 kg to -0.83 kg) with dose-dependent increase for 10 mg and 15 mg doses. The comparison between tirzepatide and semaglutide was examined in the SURPASS-2 trial that was included in this systematic review. For AEs…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Without GLP-1RA, dietary suggestions became challenging to adhere to.
“and in these data, without the use of GLP-1RA, these dietary suggestions became challenging to adhere to.27”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [27]
Calorie deficit is the primary driver of weight loss, followed by macronutrient composition.
“Meta-analysis shows calorie deficit is the primary weight loss driver, followed by macronutrient composition”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [27]
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 33,583 · see citing works
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · see citing works
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · see citing works
Analysing data and undertaking meta‐analyses
Deeks, J. J., Higgins, J. P., Altman, D. G., & on behalf of the Cochrane Statistical Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch10 · Cited by 2,672 · see citing works
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · see citing works
Doing Meta-Analysis with R: A Hands-On Guide
Harrer, M., Cuijpers, P., Furukawa, T. A., & Ebert, D. D. (2021) · doi:10.1201/9781003107347 · Cited by 1,850 · see citing works
Analysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800 · see citing works
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · see citing works
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1× · see citing works
“Also, tirzepatide’s effect on GLP-1 decreases appetite, slows down gastric emptying and reduces food consumption; GIP has also been hypothesized to improve lipid metabolism by increasing lipolysis in fasting state and lipogenesis post-meal, thereby contributing to the improvement in management of metabolic diseases an…”
BackgroundTirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · see citing works
Kinlen, D., Cody, D., & O’Shea, D. (2018) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcx152 · Cited by 308 · see citing works
Willoughby, D., Hewlings, S., & Kalman, D. (2018) · Nutrients · doi:10.3390/nu10121876 · Cited by 214 · see citing works
Dietary strategies implicated in the prevention and treatment of metabolic syndrome
De la Iglesia, R., Loria-Kohen, V., Zulet, M., Martinez, J., Reglero, G., & Ramirez de Molina, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111877 · Cited by 168 · see citing works
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111 · see citing works
Hurt, R. T., Stephenson, C. R., Gilman, E. A., Aakre, C. A., Croghan, I. T., Mundi, M. S., Ghosh, K., & Edakkanambeth Varayil, J. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251332215 · Cited by 78 · see citing works
Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R. (2024) · Clinical Epidemiology · doi:10.2147/clep.s456170 · Cited by 60 · see citing works
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19 · see citing works
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13 · see citing works
- Authors
- Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., Chung, H. C., Young, D. Y., Chan, M. Y., Khoo, C. M., Mehta, A., Muthiah, M. D., Noureddin, M., Ng, C. H., Chew, N. W. S., & Chin, Y. H.
- Affiliations
- National University of Singapore (SG)
- Nanyang Technological University (SG)
- Ministry of Health (SG)
- Virginia Commonwealth University (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Ng, Cheng Han
- Chin, Yip Han
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2023-05-31
- Volume
- 47
- Issue
- 8
- Pages
- 677-685
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4378781463
- Cited by
- 83
- References
- 15
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 30 · 2023: 4
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- DR-NTU (Nanyang Technological University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, overweight, weight loss, semaglutide, adverse events, gastrointestinal adverse effects, dose-response relationship, metabolic syndrome, drug safety, weight regain after weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
